Opportunity Information: Apply for RFA HL 19 007
This NIH funding opportunity (RFA HL 19 007) is a limited competition cooperative agreement (U01; clinical trials not allowed) to support a Data Analysis and Coordination Center (DACC) for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS). The MACS and WIHS are long-running U.S. cohort studies focused on HIV, and this announcement is aimed at funding the centralized hub that manages and coordinates the combined cohort study data infrastructure, analytic support, and consortium-wide coordination. In practical terms, the DACC is expected to serve as the backbone for high-quality, standardized data operations across the consortium so researchers can more effectively study HIV infection in the United States, especially the basic and clinical science questions and the epidemiology of HIV-related comorbidities.
The DACC role is positioned as an active member of the MACS/WIHS-CCS consortium rather than a passive data warehouse. The center would typically be responsible for coordinating data collection standards and harmonization across participating clinical sites, ensuring consistent data definitions, maintaining data quality control processes, supporting secure data management and documentation, and enabling reliable analytic workflows for consortium science. Because the scientific focus explicitly includes HIV-related comorbidities, the center would also be expected to support analyses that span aging, cardiovascular and pulmonary complications, cancer and other chronic conditions, co-infections, and other health outcomes that increasingly shape the lives of people with HIV. The DACC would also support the consortium by producing datasets, analytic files, reports, and cross-site summaries that help investigators conduct reproducible research and translate cohort observations into publishable scientific findings and, ultimately, improved understanding of HIV disease and its complications in the modern treatment era.
This FOA is paired with a companion cooperative agreement that supports the MACS/WIHS-CCS Clinical Research Sites (CRS). That pairing signals a division of labor: clinical sites focus on participant-facing research activities and data/specimen collection, while the DACC provides the centralized coordination, data stewardship, and analytic capacity that ties the network together. As a U01 cooperative agreement, the award mechanism also implies substantial NIH involvement during the project, with NIH staff typically collaborating with awardees on governance, milestones, consortium priorities, and coordination expectations, consistent with the cooperative agreement model.
Eligibility is restricted, reflecting the limited competition nature of the opportunity. The listing indicates eligible applicants include public and state-controlled institutions of higher education, and the announcement explicitly excludes non-U.S. entities. Foreign institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. Applicants are directed to consult the full funding announcement for precise eligibility and submission requirements.
Key administrative details from the source information include: the sponsoring agency is the National Institutes of Health; the opportunity category is discretionary; the activity category is education and health; and multiple CFDA numbers are associated with the announcement (93.233, 93.242, 93.279, 93.307, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.855, 93.856), reflecting the cross-institute nature of HIV and comorbidity research and the likelihood of involvement by multiple NIH institutes and centers. The announcement was created on 2017-12-22, with an original closing date of 2018-05-02. The award ceiling and expected number of awards are not specified in the provided data, so those details would need to be confirmed in the full FOA text or related NIH documentation.Apply for RFA HL 19 007
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01 Clinical Trials Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.242, 93.279, 93.307, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.855, 93.856.
- This funding opportunity was created on 2017-12-22.
- Applicants must submit their applications by 2018-05-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is this NIH funding opportunity?
This is an NIH funding opportunity announcement identified as RFA HL 19 007. It supports a limited competition cooperative agreement using the U01 mechanism, and it is specifically to fund a Data Analysis and Coordination Center (DACC) for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS).
2) What does "limited competition" mean for this opportunity?
The opportunity is described as a limited competition, meaning eligibility is restricted. The information provided indicates only certain applicant types are eligible (for example, public and state-controlled institutions of higher education), and non-U.S. entities are explicitly excluded.
3) What is being funded: a research site or a coordinating center?
This announcement funds the centralized Data Analysis and Coordination Center (DACC), not the participant-facing clinical research sites. A separate, companion cooperative agreement supports the MACS/WIHS-CCS Clinical Research Sites (CRS).
4) What is the purpose of the DACC in the MACS/WIHS-CCS consortium?
The DACC is intended to be the centralized hub that manages and coordinates the combined cohort study's data infrastructure, analytic support, and consortium-wide coordination. In practical terms, it serves as the backbone for standardized, high-quality data operations across the consortium so researchers can more effectively study HIV in the United States, including epidemiology and HIV-related comorbidities.
5) What kinds of activities is the DACC expected to perform?
Based on the provided description, typical DACC responsibilities include coordinating data collection standards and harmonization across clinical sites, ensuring consistent data definitions, maintaining data quality control processes, supporting secure data management and documentation, and enabling reliable analytic workflows. The DACC is also expected to produce datasets, analytic files, reports, and cross-site summaries that support reproducible consortium science.
6) Is the DACC expected to actively participate in the consortium's science?
Yes. The DACC role is described as an active member of the MACS/WIHS-CCS consortium rather than a passive data warehouse. This implies an operational and scientific support role that goes beyond storage, including analytic support and coordination functions that directly enable consortium research.
7) What is the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS)?
MACS and WIHS are described as long-running U.S. cohort studies focused on HIV. The MACS/WIHS-CCS refers to the combined cohort study effort that integrates these resources and requires consortium-wide data coordination.
8) Are clinical trials allowed under this funding mechanism?
No. The opportunity is described as a U01 cooperative agreement with clinical trials not allowed.
9) What is the scientific emphasis of the work supported by this DACC?
The DACC is meant to support research on HIV infection in the United States, including basic and clinical science questions and the epidemiology of HIV-related comorbidities. The description highlights analyses spanning aging, cardiovascular and pulmonary complications, cancer and other chronic conditions, co-infections, and other health outcomes affecting people with HIV.
10) How does the DACC relate to the Clinical Research Sites (CRS)?
The FOA is paired with a companion cooperative agreement that supports the MACS/WIHS-CCS Clinical Research Sites. The pairing reflects a division of labor: clinical sites conduct participant-facing research activities and data/specimen collection, while the DACC provides centralized coordination, data stewardship, and analytic capacity across the network.
11) What does the U01 cooperative agreement mechanism imply about NIH involvement?
Because this is a U01 cooperative agreement, the provided description indicates substantial NIH involvement during the project. NIH staff typically collaborate with awardees on governance, milestones, consortium priorities, and coordination expectations, consistent with the cooperative agreement model.
12) Who is eligible to apply?
The information provided indicates eligibility includes public and state-controlled institutions of higher education. It also emphasizes that eligibility is restricted due to the limited competition nature of the opportunity. Applicants are directed to consult the full announcement for precise eligibility and submission requirements.
13) Are foreign institutions or non-U.S. entities eligible to apply?
No. The provided information explicitly excludes non-U.S. entities. Foreign institutions are not eligible to apply.
14) Are non-domestic components of U.S. organizations allowed?
No. The provided information states that non-domestic components of U.S. organizations are not eligible.
15) Are foreign components allowed under this announcement?
No. Foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
16) What agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
17) What are the opportunity and activity categories listed for this announcement?
The opportunity category is listed as discretionary. The activity category is listed as education and health.
18) What CFDA numbers are associated with this opportunity?
The provided information lists multiple CFDA numbers associated with the announcement: 93.233, 93.242, 93.279, 93.307, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.855, 93.856. This is described as reflecting the cross-institute nature of HIV and comorbidity research and likely involvement by multiple NIH institutes and centers.
19) When was the announcement created and what was the original closing date?
The announcement was created on 2017-12-22, and the original closing date was 2018-05-02.
20) Is the award ceiling or expected number of awards provided?
No. The provided information states that the award ceiling and expected number of awards are not specified, and that these details would need to be confirmed in the full FOA text or related NIH documentation.
21) What kinds of deliverables might the DACC be expected to produce?
The description indicates the DACC would support the consortium by producing datasets, analytic files, reports, and cross-site summaries to help investigators conduct reproducible research and translate cohort observations into publishable scientific findings.
22) What is the practical impact the DACC is intended to have on HIV research?
The DACC is positioned to enable high-quality, standardized data operations across the consortium, making it easier for researchers to conduct reliable analyses on HIV infection and HIV-related comorbidities and to generate publishable findings that improve understanding of HIV disease and its complications in the modern treatment era.
23) Where should applicants look for exact submission and eligibility rules?
The provided information directs applicants to consult the full funding announcement for precise eligibility and submission requirements.
Browse more opportunities from the same category: Education, Health
Next opportunity: NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01 - Clinical Trial Optional)
Previous opportunity: Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 19 007
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 19 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Apply for PAR 18 559 Funding Number: PAR 18 559 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required) Apply for PAR 18 560 Funding Number: PAR 18 560 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional) Apply for PAR 18 437 Funding Number: PAR 18 437 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional) Apply for PA 18 568 Funding Number: PA 18 568 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional) Apply for PA 18 569 Funding Number: PA 18 569 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional) Apply for PA 18 603 Funding Number: PA 18 603 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional) Apply for PAR 18 605 Funding Number: PAR 18 605 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03 Clinical Trial Optional) Apply for PA 18 601 Funding Number: PA 18 601 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21 Clinical Trial Optional) Apply for PA 18 602 Funding Number: PA 18 602 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional) Apply for PAR 18 606 Funding Number: PAR 18 606 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Training Modules to Enhance the Rigor and Reproducibility of Biomedical Research (R25 Clinical Trial Not Allowed) Apply for RFA GM 18 002 Funding Number: RFA GM 18 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional) Apply for PAR 18 612 Funding Number: PAR 18 612 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional) Apply for PAR 18 611 Funding Number: PAR 18 611 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional) Apply for PAS 18 624 Funding Number: PAS 18 624 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional) Apply for PAS 18 625 Funding Number: PAS 18 625 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| NIDA Small Research Grant Program (R03 Clinical Trial Required) Apply for PA 18 626 Funding Number: PA 18 626 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| NIDA Academic Research Enhancement Award (R15, Clinical Trials Required) Apply for PA 18 627 Funding Number: PA 18 627 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Apply for PA 18 629 Funding Number: PA 18 629 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,999 |
| NIDA Small Research Grant Program (R03 Clinical Trial Required) Apply for PA 18 634 Funding Number: PA 18 634 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01 - Clinical Trial Optional) Apply for PAR 18 638 Funding Number: PAR 18 638 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 19 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.